Bevacizumab, Dacarbazine and Interferon Alfa-2a Combination as a First-Line Therapy in Patients With Locally Advancing or Metastatic Melanoma

NCT00308607 Phase 2 COMPLETED

The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with locally advancing or metastatic melanoma.

Details

Lead sponsor	University of Turku
Phase	Phase 2
Status	COMPLETED
Enrolment	27
Start date	2005-08
Completion	2009-04

Conditions

• Metastatic Melanoma

Interventions

• Bevacizumab (Avastin)
• dacarbazine
• interferon-alfa-2a (Roferon-A)

Primary outcomes

• Response rate according to RECIST criteria
• Progression-free survival
• Time to brain metastases
• Overall survival

Countries

Finland